Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06352125 · ClinicalTrials.gov registry record
An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge
A clinical trial, sponsored by Haemonetics Corporation.
- Completed
- Registry status
- 338
- Enrollment target
NCT06352125: Completed study, sponsored by Haemonetics Corporation.
NCT06352125 is a clinical trial that has completed, run by Haemonetics Corporation. The registered enrollment target is 338 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06352125 has completed, sponsored by Haemonetics Corporation.
- COMPLETED
- Registry status
- 338 participants
- Enrollment target
Study Summary
This clinical trial is designed to assess the agreement of the TEG® 6s system using the Citrated K, KH, RTH, FFH, cartridge (hereafter referred to as the Heparin Neutralization (HN) Cartridge) with its comparators.
Primary Outcome
CK-MA TEG Parameter. Unit of measurement was mm.
Interventions
- DIAGNOSTIC_TEST Clauss Fibrinogen
- DIAGNOSTIC_TEST TEG 6s Citrated K, KH, RTH, FFH Cartridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2023-01-31 |
What the finished NCT06352125 record still lists
NCT06352125 is an observational study that tracks outcomes without assigning an intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Clauss Fibrinogen is the first listed.
NCT06352125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06352125 about?
NCT06352125 is a clinical study titled "An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge". This clinical trial is designed to assess the agreement of the TEG® 6s system using the Citrated K, KH, RTH, FFH, cartridge (hereafter referred to as the Heparin Neutralization (HN) Cartridge) with its comparators.
What is the current status of trial NCT06352125?
This trial is currently completed. The enrollment target is 338 participants. The study started on 2021-12-09. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT06352125?
The interventions under investigation include: Clauss Fibrinogen (DIAGNOSTIC_TEST), TEG 6s Citrated K, KH, RTH, FFH Cartridge (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06352125?
This trial is sponsored by Haemonetics Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI